Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beam Therapeutics (BEAM) Shares Issued: 2019-2024

Historic Shares Issued for Beam Therapeutics (BEAM) over the last 6 years, with Dec 2024 value amounting to $5.6 million.

  • Beam Therapeutics' Shares Issued fell 41.64% to $412,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $5.9 million, marking a year-over-year decrease of 84.39%. This contributed to the annual value of $5.6 million for FY2024, which is 97.63% down from last year.
  • As of FY2024, Beam Therapeutics' Shares Issued stood at $5.6 million, which was down 97.63% from $236.6 million recorded in FY2023.
  • Beam Therapeutics' Shares Issued's 5-year high stood at $757.4 million during FY2021, with a 5-year trough of $5.6 million in FY2024.
  • Moreover, its 3-year median value for Shares Issued was $108.3 million (2022), whereas its average is $116.8 million.
  • As far as peak fluctuations go, Beam Therapeutics' Shares Issued soared by 103,959.46% in 2020, and later tumbled by 97.63% in 2024.
  • Beam Therapeutics' Shares Issued (Yearly) stood at $192.5 million in 2020, then soared by 293.46% to $757.4 million in 2021, then plummeted by 85.71% to $108.3 million in 2022, then surged by 118.52% to $236.6 million in 2023, then slumped by 97.63% to $5.6 million in 2024.